Share

May 06, 2014; 82 (18) Article

Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy

M. Toledano, J.W. Britton, A. McKeon, C. Shin, V.A. Lennon, A.M.L. Quek, E. So, G.A. Worrell, G.D. Cascino, C.J. Klein, T.D. Lagerlund, E.C. Wirrell, K.C. Nickels, S.J. Pittock
First published April 4, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000383
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2060

Share

Article Information

vol. 82 no. 18 1578-1586
DOI: 
https://doi.org/10.1212/WNL.0000000000000383
PubMed: 
24706013
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 22, 2013
  • Accepted in final form January 6, 2014
  • First Published April 4, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. M. Toledano, MD,
    2. J.W. Britton, MD,
    3. A. McKeon, MD,
    4. C. Shin, MD,
    5. V.A. Lennon, MD, PhD,
    6. A.M.L. Quek, MBBS,
    7. E. So, MD,
    8. G.A. Worrell, MD, PhD,
    9. G.D. Cascino, MD,
    10. C.J. Klein, MD,
    11. T.D. Lagerlund, MD,
    12. E.C. Wirrell, MD,
    13. K.C. Nickels, MD and
    14. S.J. Pittock, MD
  1. M. Toledano, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. J.W. Britton, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mr. and Mrs. David Hawk charitable gift for epilepsy research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. A. McKeon, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. C. Shin, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. V.A. Lennon, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. They have received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies. The author receives no royalties from the sale of these tests by Mayo Medical Laboratories; however, Mayo Collaborative Services, Inc. does receive revenue for conducting these tests.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Dr. Lennon is Director of the Mayo Neuroimmunology Laboratory that performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Neither Dr. Lennon nor her laboratory benefit financially from this testing.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. “Marker for Neuromyelitis Optica”. A patent has been issued to Mayo Foundation for this technology, and it has been licensed to RSR/Kronus. Dr. Lennon has received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies.

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below: “Marker for Neuromyelitis Optica”.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. A.M.L. Quek, MBBS,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. E. So, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Clinical Neurophysiology, editorial board member, 4 years; Epilepsia, editorial board member, 2 years; Epilepsy Research, editorial board member, 3 years.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. G.A. Worrell, MD, PhD,
    9. Scientific Advisory Boards:

    1. NeuroVista Inc.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor of Transaction in Biomedical Engineering

    Patents:

    1. Filed patent: Microscale Electrophysiology for mapping epileptogenic brain and predicting seizures

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) NeuroVista Inc. 2) Meditronic Inc.

    Research Support, Government Entities:

    1. NIH R01 NS 63039-1, PI: Worrell 04/01/2009 ? 03/31/2014 European Union Agreement FP 00066387 Co-I: Worrell 11/01/2011-12/31/2015 NeuroPace, Inc 15682PI: Worrell 11/01/2007 -?10/31/2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. G.D. Cascino, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NEUROLOGY -- Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01 NS53998-03 (PI) grant (EPGP: Epilepsy Phenome Genome project)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Mayo Foundation- Mayo Clinic Ventures-High frequency nerve stimulation to treat lower back pain, Nevro, 2013

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. C.J. Klein, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board Journal of Peripheral Nerve Society.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. K08NS065007 funded by NINDS principal instigator IDENTIFICATION OF GENETIC CAUSES OF HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES Project Start Date: 1-SEP-2009 Project End Date: 30-AUG-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. T.D. Lagerlund, MD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. E.C. Wirrell, MD,
    13. Scientific Advisory Boards:

    1. Clobazam for Dravet syndrome study - all monies to Mayo with no personal reimbursement

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Epilepsia Editorial Board 2010-2012, Journal of Child Neurology Editorial Board 2007-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Biocodex - research support for multicenter US Stiripentol study in Dravet syndrome

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mayo Foundation, CR 20 Award, 2009-2011

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. K.C. Nickels, MD and
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. S.J. Pittock, MD
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock and Mayo Clinic have a financial interest in the technology entitled “Aquaporin-4 Autoantibody as a Cancer Marker.” This technology has been licensed to a commercial entity but no royalties have been received. In addition, Dr. Pittock is an inventor of technology entitled “Aquaporin-4 Binding Autoantibodies in Patients with Neuromyelitis Optic Impair Glutamate Transport by Down-Regulating EAAT2.” Mayo Clinic has filed a non-provisional patent application for this technology.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled “An Open Label Study of Eculizumab in NMO”

    Research Support, Government Entities:

    1. RO1 NS065829-01 entitled ?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation grant for NMO research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (M.T., J.W.B., A.M., C.S., V.A.L., E.S., G.A.W., G.D.C., C.J.K., T.D.L., E.C.W., K.C.N., S.J.P.), Laboratory Medicine and Pathology (A.M., V.A.L., A.M.L.Q., C.J.K., S.J.P.), and Immunology (V.A.L.), Mayo Clinic, College of Medicine, Rochester, MN.
  1. Correspondence to Dr. Pittock: pittock.sean{at}mayo.edu
View Full Text

Article usage

Article usage: April 2014 to January 2021

AbstractFullPdfSource
Apr 2014830198Highwire
May 20142948120244Highwire
Jun 20144115294Highwire
Jul 20142943848Highwire
Aug 20141511440Highwire
Sep 20141461721Highwire
Oct 20141491328Highwire
Nov 20141651427Highwire
Dec 2014861622Highwire
Jan 20151953330Highwire
Feb 20151201017Highwire
Mar 20151691314Highwire
Apr 20151651625Highwire
May 2015162720Highwire
May 201502623pmc
Jun 201513256Highwire
Jun 201503528pmc
Jul 2015166511Highwire
Jul 201504224pmc
Aug 201513536Highwire
Aug 201504729pmc
Sep 20151131315Highwire
Sep 201503923pmc
Oct 201511174Highwire
Oct 201502720pmc
Nov 201510777Highwire
Nov 201504842pmc
Dec 201512346Highwire
Dec 201503428pmc
Jan 2016102812Highwire
Jan 201603928pmc
Feb 20167875Highwire
Feb 201604026pmc
Mar 2016851113Highwire
Mar 201603427pmc
Apr 201680412Highwire
Apr 201604525pmc
May 201695413Highwire
May 201603125pmc
Jun 201610386Highwire
Jun 201603326pmc
Jul 20169276Highwire
Jul 201603621pmc
Aug 201612736Highwire
Aug 201602516pmc
Sep 201614434Highwire
Sep 201603616pmc
Oct 2016106710Highwire
Oct 201603616pmc
Nov 20169089Highwire
Nov 201604126pmc
Dec 20167348Highwire
Dec 201602818pmc
Jan 201789811Highwire
Jan 201704123pmc
Feb 201710957Highwire
Feb 201704020pmc
Mar 20177489Highwire
Mar 201702812pmc
Apr 201780812Highwire
Apr 2017173340pmc
May 20178638Highwire
May 2017223337pmc
Jun 201710828Highwire
Jun 2017142628pmc
Jul 201712843Highwire
Jul 2017132020pmc
Aug 2017118312Highwire
Aug 2017233229pmc
Sep 20179248Highwire
Sep 2017284765pmc
Oct 2017101713Highwire
Oct 2017264244pmc
Nov 20179067Highwire
Nov 2017233842pmc
Dec 20174750Highwire
Jan 20184473Highwire
Feb 20188953Highwire
Mar 20181111110Highwire
Apr 20184933Highwire
Apr 2018122122pmc
May 201810156Highwire
Jun 2018113138Highwire
Jun 2018173133pmc
Jul 20188793Highwire
Aug 20188921Highwire
Aug 2018142832pmc
Sep 201812966Highwire
Oct 201886105Highwire
Nov 20188694Highwire
Dec 20186895Highwire
Jan 20199983Highwire
Feb 201964108Highwire
Mar 20196875Highwire
Apr 20199254Highwire
May 20194857Highwire
Jun 20196453Highwire
Jul 20199066Highwire
Aug 20196167Highwire
Sep 20196702Highwire
Oct 20196265Highwire
Nov 20195197Highwire
Dec 20194623Highwire
Jan 20205670Highwire
Feb 20205734Highwire
Mar 20205953Highwire
Apr 20205273Highwire
May 20206033Highwire
Jun 20205611Highwire
Jul 20207173Highwire
Aug 20204501Highwire
Sep 20206351Highwire
Oct 20206230Highwire
Nov 20207922Highwire
Dec 20205020Highwire
Jan 20215033Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me